Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: A pilot study

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 3, 2013, Pages 280-288

  O'Brien, Meagan ^a,b   Montenont, Emilie ^a   Hu, Liang ^a   Nardi, Michael A ^a   Valdes, Vanessa ^a   Merolla, Michael ^a   Gettenberg, Gabrielle ^a   Cavanagh, Karen ^a,b   Aberg, Judith A ^a,b   Bhardwaj, Nina ^c   Berger, Jeffrey S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BELLEVUE HOSPITAL CENTER   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Aggregation; Aspirin; HIV 1; Immune activation; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; HLA DR ANTIGEN; TOLL LIKE RECEPTOR;

ADULT; AGED; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; ATTENUATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNITY; IMMUNOMODULATION; IN VITRO STUDY; LEUKOCYTE; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; MONOCYTE; PILOT STUDY; PRIORITY JOURNAL; STIMULATION; T LYMPHOCYTE ACTIVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT DURATION;

ADENOSINE DIPHOSPHATE; ADULT; AGED; ANTI-HIV AGENTS; ARACHIDONIC ACID; ASPIRIN; CELLS, CULTURED; COLLAGEN; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; P-SELECTIN; PILOT PROJECTS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; THROMBOXANES; YOUNG ADULT;

EID: 84880246969     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31828a292c     Document Type: Article

References (43)

1. Triant VA. HIV-1 infection and coronary heart disease: an intersection of epidemics. J Infect Dis. 2012;205(suppl 3):S355-S361.
2. Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the riskofcardiovascular disease in HIV-1-infected patients: the data collection on adverse effects of anti-HIV-1 drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17:491-501.
3. Aberg JA. Cardiovascular complications in HIV-1 management: past, present, and future. J Acquir Immune Defic Syndr. 2009;50:54-64.
4. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
5. Lang S, Mary-Krause M, Simon A, et al. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis. 2012;55:600-607.
6. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV-1 outpatient study. Clin Infect Dis. 2010;51:435-447.
7. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179:859-870.
8. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881-1888.
9. Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV-1. AIDS. 2010;24:697-706.
10. Mayne E, Funderburg NT, Sieg SF, et al. Increased platelet and micropar-ticle activation in HIV-1 infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr. 2012;59:340-346.
11. Singh MV, Davidson DC, Kiebala M, et al. Detection of circulating platelet-monocyte complexes in persons infected with human immunodeficiency virus type-1. J Virol Methods. 2012;181:170-176.
12. Lievens D, Zernecke A, Seijkens T, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood. 2010; 116:4317-4327.
13. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arte-rioscler Thromb Vasc Biol. 2003;23:2131-2137.
14. Trip MD, Cats VM, van Capelle FJ, et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;322: 1549-1554.
15. Duffau P, Seneschal J, Nicco C, et al. Platelet CD154 potentiates inter-feron-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med. 2010;2:47ra63.
16. Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. J Thromb Hae-most. 2011;9:1097-1107.
17. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987;316:1514-1518.
18. Merolla M, Nardi MA, Berger JS. Centrifugation speed affects light transmission aggregometry. Int J Lab Hematol. 2012;34:81-85.
19. Rossio JL, Esser MT, Suryanarayana K, et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol. 1998;72:7992-8001.
20. Berger JS, Becker RC, Kuhn C, et al. Hyperreactive platelet phenotypes: Relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co stimulation. Thromb Haemost. 2013;109:85-92.
21. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491-495.
22. Ronsholt FF, Ullum H, Katzenstein TL, et al. T cell subset distribution in HIV-1-1 infected patients after 12 years of treatment induced viraemic suppression. J Acquir Immune Defic Syndr. 2012;61:270-278.
23. Rueda CM, Velilla PA, Chougnet CA, et al. HIV-1-induced T-cell activation/exhaustion in rectal mucosa is controlled only partially by antire-troviral treatment. PLoS One. 2012;7:e30307.
24. Schroecksnadel K, Winkler C, Wirleitner B, et al. Aspirin down-regulates tryptophan degradation in stimulated human peripheral blood mono-nuclear cells in vitro. Clin Exp Immunol. 2005;140:41-45.
25. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956-959.
26. Kamga I, Kahi S, Develioglu L, et al. Type I interferon production is profoundly and transiently impaired in primary HIV-1-1 infection. J Infect Dis. 2005;192:303-310.
27. Donaghy H, Gazzard B, Gotch F, et al. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1-1. Blood. 2003;101:4505-4511.
28. Finke JS, Shodell M, Shah K, et al. Dendritic cell numbers in the blood of HIV-1-1 infected patients before and after changes in antiretroviral therapy. J Clin Immunol. 2004;24:647-652.
29. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV-1. Curr Opin HIV-1 AIDS. 2010;5:498-503.
30. Eastburn A, Scherzer R, Zolopa AR, et al. Association of low level viremia with inflammation and mortality in HIV-1-infected adults. PLoS One. 2011; 6:e26320.
31. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203:1637-1646.
32. Tseng ZH, Secemsky EA, Dowdy D, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Car-diol. 2012;59:1891-1896.
33. Triant VA, Regan S, Lee H, et al. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr. 2010;55:615-619.
34. van Lelyveld SF, Gras L, Kesselring A, et al. Long-term complications in patients with poor immunological recovery despite virolog-ical successful HAART in Dutch ATHENA cohort. AIDS. 2012;26: 465-474.
35. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-1-infected women. J Infect Dis. 2011;203:452-463.
36. McBane RD II, Karnicki K, Tahirkheli N, et al. Platelet characteristics associated with coronary artery disease. J Thromb Haemost. 2003;1: 1296-1303.
37. O'Brien JR. "Exhausted" platelets continue to circulate. Lancet. 1978;2: 1316-1317.
38. Shiraki R, Inoue N, Kawasaki S, et al. Expression of Toll-like receptors on human platelets. Thromb Res. 2004;113:379-385.
39. Jayachandran M, Brunn GJ, Karnicki K, et al. In vivo effects of lipo-polysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk. J Appl Physiol. 2007;102:429-433.
40. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007;100:27-40.
41. Elzey BD, Schmidt NW, Crist SA, et al. Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge. Blood. 2008;111:3684-3691.
42. Weyrich AS, McIntyre TM, McEver RP, et al. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest. 1995;95:2297-2303.
43. Cho JY. Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. Arch Pharm Res. 2007;30:64-74. Science Allergy and Infectious Diseases